Table 1 Comparison of clinical features with cases described in the literature
Author (year) | Number of cases | Time between first dose and onset of symptoms (days) | Empiric treatment | PCR for herpetic etiology study | Bilateral compromise | Anterior chamber cellularity | Transillumination defects | Pigment dispersion at gonioscopy | IOP OD; OS (mmHg) | BCVA OD; OS | Posterior subcapsular opacity | Glaucoma | Ahmed glaucoma valve |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Rivera-Valdivia (present case) | 1 | 14 | Systemic antiviral and IMT | HSV (−) VZV (−) CMV (−) EBV (−) Mycobacteria (−) Toxoplasma (−) | + | + | + | + | 30; 28 | 20/20; 20/40 | + | + | + |
Plaza-Ramos et al. (2018) | 1 | 42 | − | − | + | − | + | + | 18; 18 | 20/20; 20/40 | − | − | − |
Rangel et al. (2017) | 1 | 10 | − | − | + | − | + | + | 12; 12 | 20/20 | − | − | − |
Broens et al. (2016) | 1 | 13 | − | − | + | − | + | + | 16; 16 | 20/20 | − | − | − |
Knape et al. (2013) | 1 | 3 | − | HSV (−) VZV (−) CMV (−) | + | − | + | + | 35; 35 | 20/30; 20/40 | − | ND | ND |
Duncombe et al. (2013) | 1 | 11 | Systemic antiviral | HSV (−) VZV (−) CMV (−) EBV (−) | + | − | + | + | 50; 28 | 20/25 | − | − | − |
Nascimento et al. (2013) | 3 | 60–90 | − | − | + (2 pt) | + (1 pt) | + | + (1 pt) | 14; 14 16; 16 12; 12 | 20/20; 20/20 20/20; 20/20 20/20; 20/30 | − | − | − |
Morshedi et al. (2012) | 2 | 15–18 | − | − | + | + | + | + | 15; 26 15; 17 | 20/30; 20/40 20/20; 20/20 | + (1 pt) | − | − |
Willermain et al. (2010) | 1 | 15 | − | Herpes viruses (−) | + | + | + | + | 46; 46 | 20/200; 20/200 | − | − | − |
Wefers Bettink-Remeijer et al. (2009) | 5 | 10–14 | − | HSV (1 pt +) | + | + (2 pt) | + | − | ND | ND | ND | ND | ND |
Bringas Calvo et al. (2004) | 1 | 10 | − | − | + | + | + | + | 9; 8 | 20/25; 20/30 | − | − | − |